Correlation between serum GDF15 level and circulating insulin resistance in patients with polycystic ovary syndrome

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100045692

Enrollment

Unknown

Registered

2021-04-23

Start date

2021-04-25

Completion date

Unknown

Last updated

2021-12-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polycystic ovary syndrome

Interventions

Normal women group:Euglycemic-hyperinsulinemic clamp

Patients with polycystic ovary syndrome group:Euglycemic-hyperinsulinemic clamp

Eligibility

Sex/Gender

Female

Age

15 Years to 35 Years

Inclusion criteria

Inclusion criteria: 1. Sparse ovulation or no ovulation; 2. Clinical or biochemical manifestations of high androgen; 3. Ultrasound indicates ovarian polycystic ovary, but excludes other diseases that can cause hyperandrogenism and ovulation disorders, such as 21-hydroxylase deficiency, congenital adrenal hyperplasia, Cushing's syndrome, thyroid disease, hyperprolactinemia Disease and so on. All healthy people have normal blood sugar and no clinical or biochemical manifestations of hyperandrogen.

Exclusion criteria

Exclusion criteria: 1. Aged > 40 years, BMI > 35 kg/m2; 2. Cardiovascular disease, thyroid disease, tumor, smoking, diabetes, high blood pressure, impaired renal function (serum creatinine> 120 µmol/l).

Design outcomes

Primary

Measure	Time frame
Growth differentiation factor15;	—

Countries

China

Contacts

Public ContactLiao Xin

The Affiliated Hospital of Zunyi Medical University

liaoxin8618@163.com+86 13595208618

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026